Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma
Alexander C. J. van Akkooi(The University of Sydney), Johannes H. W. de Wilt(Radboud University Nijmegen), R. Hoedemaker(Erasmus MC), Alexander M.M. Eggermont(University Medical Center Utrecht), Dirk J. Grünhagen(Erasmus MC), Paul Schmitz(University Hospital Regensburg), Cornelis Verhoef(Erasmus MC Cancer Institute), A.N. van Geel(Erasmus MC), Marna G. Bouwhuis(Erasmus MC)
Cited by 135
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k